GTBP (gtbiopharma.com) Business Value to Revenue

The enterprise value assessment of GT Biopharma, Inc. (GTBP) via EV/Sales demonstrates a sharp surge, contrasting with the TriKE clinical trial phase. The 0.00 metric reflects current dynamics driven by a lack of operating revenues and a reliance on partnerships. This high multiple is attributed to the colossal R&D potential in the NK-cell sector, which provides the company with technological leadership in oncohematology therapy.
GTBP (GT Biopharma): analytical breakdowns and indicator data

Analyzing the EV/Revenue multiple allows for a real-time assessment of GT Biopharma, Inc. (GTBP) as a biotech startup that leverages research alliances to develop anti-tumor drugs. This indicator compares the total enterprise value to sales figures excluding leverage, enabling investors to identify hidden debt risks and determine the actual resilience of the capitalization amid tight monetary policy.